← Back to Screener
ScreenerNewsCompareWatchlist
VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesNewsCompareWatchlist
AnalyzeValuationTotal ReturnDCA CalculatorInsider Activity

MNKD logoMannKind Corporation(MNKD)Earnings, Financials & Key Ratios

MNKD•NASDAQ
$3.56
$1.1B mkt cap·178.0× P/E·Price updated May 6, 2026
SectorHealthcareIndustryBiotechnologySub-IndustryMetabolic and Obesity Therapies
AboutMannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.Show more
  • Revenue$349M+22.2%
  • EBITDA$51M-37.4%
  • Net Income$6M-78.7%
  • EPS (Diluted)0.02-79.4%
  • Gross Margin82.47%+12.7%
  • EBITDA Margin14.64%-48.8%
  • Operating Margin11.12%-56.3%
  • Net Margin1.68%-82.6%
  • ROIC21.55%
  • Interest Coverage1.10-38.9%
Technical→

MNKD Key Insights

MannKind Corporation (MNKD) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

  • ✓High quality earnings: Operating CF exceeds net income
  • ✓Strong 5Y sales CAGR of 39.9%

✗Weaknesses

  • ✗Weak momentum: RS Rating 11 (bottom 11%)
  • ✗Shares diluted 10.7% in last year
  • ✗Trading more than 30% below 52-week high

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

MNKD Price & Volume

MannKind Corporation (MNKD) stock price & volume — 10-year historical chart

Loading chart...

MNKD Growth Metrics

MannKind Corporation (MNKD) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-
5 Years39.89%
3 Years51.8%
TTM21.23%

Profit CAGR

10 Years-
5 Years-
3 Years-
TTM-179.41%

EPS CAGR

10 Years-
5 Years-
3 Years-
TTM-171.51%

Return on Capital

10 Years-220%
5 Years-4.74%
3 Years10.82%
Last Year8.32%

MNKD Recent Earnings

MannKind Corporation (MNKD) EPS & revenue vs analyst estimates — last 4 quarters

Full history →
●Beat EPS 6/12 qtrs (55%)●Beat Revenue 8/12 qtrs (67%)
Q1 2026Latest
Feb 26, 2026
EPS
$0.05
Est $0.01
-400.0%
Revenue
$112M
Est $98M
+14.7%
Q4 2025
Nov 5, 2025
EPS
$0.03
Est $0.01
+200.0%
Revenue
$82M
Est $100M
-17.7%
Q3 2025
Aug 6, 2025
EPS
$0.00
Est $0.04
-94.7%
Revenue
$77M
Est $80M
-4.5%
Q2 2025
May 8, 2025
EPS
$0.04
Est $0.03
+33.3%
Revenue
$78M
Est $78M
-0.1%
QuarterDateEPS (Act vs Est)Revenue (Act vs Est)
Q1 2026LatestFeb 26, 2026
$0.05vs $0.01-400.0%
$112Mvs $98M+14.7%
Q4 2025Nov 5, 2025
$0.03vs $0.01+200.0%
$82Mvs $100M-17.7%
Q3 2025Aug 6, 2025
$0.00vs $0.04-94.7%
$77Mvs $80M-4.5%
Q2 2025May 8, 2025
$0.04vs $0.03+33.3%
$78Mvs $78M-0.1%
Based on last 12 quarters of dataView full earnings history →

MNKD Peer Comparison

MannKind Corporation (MNKD) competitors in Metabolic and Obesity Therapies — business model, growth, and fundamentals comparison

Select Columns
Stock Universe
Valuation
Growth
Profitability
Financial Health
Dividends & Buybacks
Price Performance
Technical
Fundamentals ($)
Sector-Specific
CompanyMarket CapStock PriceP/E Ratio (TTM)Revenue Growth 1YNet MarginReturn on Equity (ROE)FCF YieldDebt / Equity
UTHR logoUTHRUnited Therapeutics CorporationDirect Competitor26.13B596.1321.4010.61%40.61%19.24%
INSM logoINSMInsmed IncorporatedDirect Competitor29.14B137.09-21.3566.73%-264.83%-125.2%0.06
ACAD logoACADACADIA Pharmaceuticals Inc.Direct Competitor3.68B21.489.3811.87%36.49%41.9%0.04
PTCT logoPTCTPTC Therapeutics, Inc.Direct Competitor5.52B66.618.56114.51%39.44%
RARE logoRAREUltragenyx Pharmaceutical Inc.Direct Competitor2.55B25.93-4.4520.13%-91.03%-6.08%
NVO logoNVONovo Nordisk A/SProduct Competitor203.36B45.7612.656.43%33.14%61.1%0.67
SNY logoSNYSanofiProduct Competitor105.71B43.7718.375.49%16.72%10.78%0.30
LLY logoLLYEli Lilly and CompanyProduct Competitor932.64B987.1143.0144.7%34.98%101.17%1.60

Compare MNKD vs Peers

MannKind Corporation (MNKD) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs UTHR

Most directly comparable listed peer for MNKD.

Scale Benchmark

vs LLY

Larger-name benchmark to compare MNKD against a more recognizable public peer.

Peer Set

Compare Top 5

vs UTHR, INSM, ACAD, PTCT

MNKD Income Statement

MannKind Corporation (MNKD) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily
Line itemDec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25TTM
Sales/Revenue11.74M27.86M63.04M65.14M75.44M99.77M198.96M285.5M348.97M360.78M
Revenue Growth %-93.28%137.2%126.28%3.34%15.81%32.25%99.42%43.5%22.23%21.23%
Cost of Goods Sold17.23M20.48M27.98M24.64M38.86M57.5M62.77M76.6M61.16M74.86M
COGS % of Revenue146.68%73.51%44.38%37.83%51.51%57.63%31.55%26.83%17.53%-
Gross Profit
-5.48M▲ 0%
7.38M▲ 234.6%
35.06M▲ 375.1%
40.5M▲ 15.5%
36.59M▼ 9.7%
42.27M▲ 15.5%
136.19M▲ 222.2%
208.9M▲ 53.4%
287.81M▲ 37.8%
285.93M▲ 0%
Gross Margin %-46.68%26.49%55.62%62.17%48.49%42.37%68.45%73.17%82.47%79.25%
Gross Profit Growth %-104.4%234.6%375.05%15.53%-9.67%15.55%222.17%53.39%37.77%-
Operating Expenses88.86M88.44M79.66M88.42M83.61M106.38M127.51M136.31M249M260.65M
OpEx % of Revenue756.59%317.47%126.36%135.72%110.82%106.63%64.09%47.75%71.36%-
Selling, General & Admin74.96M79.72M74.67M59.04M77.42M91.47M94.31M94.33M144.13M173.21M
SG&A % of Revenue638.22%286.14%118.45%90.63%102.62%91.68%47.4%33.04%41.3%-
Research & Development14.12M8.74M6.9M6.25M12.31M19.72M31.28M45.89M66.35M72.56M
R&D % of Revenue120.2%31.36%10.95%9.59%16.32%19.77%15.72%16.07%19.01%-
Other Operating Expenses13K-437K-1.91M23.13M-6.12M-4.81M1.92M-3.91M38.52M2M
Operating Income
-108.19M▲ 0%
-76.59M▲ 29.2%
-44.6M▲ 41.8%
-47.91M▼ 7.4%
-47.02M▲ 1.9%
-64.11M▼ 36.3%
8.68M▲ 113.5%
72.59M▲ 736.4%
38.8M▼ 46.5%
14.72M▲ 0%
Operating Margin %-921.15%-274.94%-70.75%-73.55%-62.33%-64.26%4.36%25.42%11.12%4.08%
Operating Income Growth %-260.85%29.2%41.78%-7.44%1.86%-36.34%113.54%736.45%-46.55%-
EBITDA-106.39M-74.89M-42.44M-44.59M-43.78M-57.8M13.21M81.56M51.09M25.36M
EBITDA Margin %-905.82%-268.84%-67.33%-68.44%-58.03%-57.93%6.64%28.57%14.64%7.03%
EBITDA Growth %-252.73%29.6%43.33%-5.05%1.81%-32.03%122.86%517.23%-37.36%-71.24%
D&A (Non-Cash Add-back)1.8M1.7M2.15M3.33M3.24M6.31M4.54M8.97M12.28M10.64M
EBIT-104.01M-77.3M-41M-47.99M-64.35M-62.63M10.59M68.5M15.24M14.46M
Net Interest Income-12.98M-8.94M-9.91M-9.3M-16.46M-22.26M-19.01M-25.37M-13.83M-18.43M
Interest Income293K501K997K167K112K2.51M6.15M12.62M08.25M
Interest Expense13.28M9.44M10.91M9.47M16.58M24.77M25.16M37.98M13.83M19.2M
Other Income/Expense-9.09M-10.14M-7.31M-9.54M-33.9M-23.29M-19.05M-42.07M-37.39M-43.3M
Pretax Income
-117.28M▲ 0%
-86.73M▲ 26.0%
-51.9M▲ 40.2%
-57.46M▼ 10.7%
-80.93M▼ 40.8%
-87.4M▼ 8.0%
-10.38M▲ 88.1%
30.52M▲ 394.1%
1.41M▼ 95.4%
-28.58M▲ 0%
Pretax Margin %-998.57%-311.34%-82.34%-88.2%-107.27%-87.6%-5.22%10.69%0.4%-7.92%
Income Tax51K240K0-218K001.56M2.93M-4.46M-4.66M
Effective Tax Rate %-0.04%-0.28%0%0.38%0%0%-15.04%9.6%-316.7%16.31%
Net Income
-117.33M▲ 0%
-86.97M▲ 25.9%
-51.9M▲ 40.3%
-57.24M▼ 10.3%
-80.93M▼ 41.4%
-87.4M▼ 8.0%
-11.94M▲ 86.3%
27.59M▲ 331.1%
5.86M▼ 78.7%
-23.91M▲ 0%
Net Margin %-999%-312.2%-82.34%-87.87%-107.27%-87.6%-6%9.66%1.68%-6.63%
Net Income Growth %-193.37%25.87%40.32%-10.28%-41.38%-8%86.34%331.09%-78.75%-179.41%
Net Income (Continuing)-117.33M-86.97M-51.9M-57.24M-80.93M-87.4M-11.94M27.59M5.86M-23.91M
Discontinued Operations0000000000
Minority Interest0000000000
EPS (Diluted)
-1.13▲ 0%
-0.60▲ 46.9%
-0.31▲ 48.3%
-0.26▲ 16.1%
-0.37▼ 42.3%
-0.44▼ 18.9%
-0.04▲ 89.8%
0.10▲ 317.4%
0.02▼ 79.4%
-0.08▲ 0%
EPS Growth %-183.09%46.9%48.33%16.13%-42.31%-18.92%89.84%317.45%-79.42%-171.51%
EPS (Basic)-1.13-0.60-0.31-0.26-0.37-0.44-0.040.100.02-
Diluted Shares Outstanding104.25M144.14M195.58M222.59M249.24M257.09M267.01M283.84M314.11M308.27M
Basic Shares Outstanding103.83M144.14M195.58M222.59M249.24M257.09M267.01M274.42M305.64M308.27M
Dividend Payout Ratio----------

MNKD Balance Sheet

MannKind Corporation (MNKD) balance sheet — assets, liabilities & shareholders' equity

Line itemDec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25TTM
Total Current Assets57.22M81.85M60.76M79.48M219.49M234.9M373.39M268.31M291.58M251.16M
Cash & Short-Term Investments43.95M71.16M49.88M67M204.12M170.85M295.1M197.26M171.35M133.86M
Cash Only43.95M71.16M29.91M67M124.18M69.77M238.48M46.34M74.88M52.83M
Short-Term Investments0019.98M079.93M101.08M56.62M150.92M96.46M81.03M
Accounts Receivable2.79M4.02M3.51M4.22M4.74M16.8M14.9M11.8M38.37M28.14M
Days Sales Outstanding86.6752.6320.3423.6322.9361.4727.3415.0940.1328.46
Inventory2.66M3.6M4.16M4.97M7.15M21.77M28.55M27.89M35.31M49.17M
Days Inventory Outstanding56.2964.1154.273.6667.18138.21165.98132.87210.75170.59
Other Current Assets5.21M527K316K158K025.48M34.85M31.36M46.55M40M
Total Non-Current Assets27.36M25.85M32.97M29.13M101.67M60.39M101.81M125.54M500.6M493.24M
Property, Plant & Equipment26.92M25.6M26.78M25.87M36.61M45.13M84.22M85.36M82.42M82.55M
Fixed Asset Turnover0.44x1.09x2.35x2.52x2.06x2.21x2.36x3.34x4.23x4.22x
Goodwill000002.43M1.93M1.93M67.59M67.59M
Intangible Assets000001.15M1.07M5.26M5.07M5.02M
Long-Term Investments000056.62M1.96M7.16M5.48M5.01M54.22M
Other Non-Current Assets437K249K6.19M3.27M8.44M9.72M7.43M27.49M340.5M706.77M
Total Assets
84.58M▲ 0%
107.7M▲ 27.3%
93.72M▼ 13.0%
108.61M▲ 15.9%
321.16M▲ 195.7%
295.28M▼ 8.1%
475.2M▲ 60.9%
393.84M▼ 17.1%
792.18M▲ 101.1%
744.4M▲ 0%
Asset Turnover0.14x0.26x0.67x0.60x0.23x0.34x0.42x0.72x0.44x0.59x
Asset Growth %-21%27.35%-12.98%15.88%195.71%-8.06%60.93%-17.12%101.14%181.96%
Total Current Liabilities87.6M75.24M65.62M73.7M48.35M67.3M104.13M81.84M171.03M134.56M
Accounts Payable6.98M5.38M4.79M5.58M6.96M11.05M9.58M6.79M9.03M16.14M
Days Payables Outstanding147.9795.8762.4782.6865.3470.1655.7132.3653.9152.06
Short-Term Debt52.74M11.3M5.03M4.06M6.98M9.56M20M049.24M0
Deferred Revenue (Current)3.04M50.87M32.5M33.27M827K1.73M9.09M12.41M15.33M47.93M
Other Current Liabilities12.97M46.76M10.13M13.46M9.53M16.43M30.97M30.37M97.43M123.04M
Current Ratio0.65x1.09x0.93x1.08x4.54x3.49x3.59x3.28x1.70x1.70x
Quick Ratio0.62x1.04x0.86x1.01x4.39x3.17x3.31x2.94x1.50x1.50x
Cash Conversion Cycle-520.8712.0714.6124.77129.52137.61115.6196.96146.99
Total Non-Current Liabilities211.71M207.55M218.63M215.32M482.16M478.52M617.24M390.82M672.17M669.04M
Long-Term Debt104.08M91.19M113.87M118.17M281.2M273.49M248.7M36.05M320.36M10.28M
Capital Lease Obligations002.51M1.2M1.04M5.34M3.92M11.64M103.78M218M
Deferred Tax Liabilities-500K-10.68M00000000
Other Non-Current Liabilities107.63M105.68M93.9M94.28M175.43M162.01M294.82M291.97M208.05M1.37B
Total Liabilities299.31M282.79M284.25M289.03M530.51M545.82M721.37M472.66M843.2M803.6M
Total Debt156.82M102.49M121.41M123.44M289.22M288.4M272.62M47.7M473.38M10.28M
Net Debt112.88M31.33M91.51M56.43M165.03M218.63M34.14M1.36M398.5M-42.55M
Debt / Equity----------0.17x
Debt / EBITDA------20.63x0.58x9.27x0.41x
Net Debt / EBITDA------2.58x0.02x7.80x7.80x
Interest Coverage-7.83x-8.19x-3.76x-5.07x-3.88x-2.53x0.42x1.80x1.10x0.75x
Total Equity
-214.73M▲ 0%
-175.08M▲ 18.5%
-190.53M▼ 8.8%
-180.42M▲ 5.3%
-209.35M▼ 16.0%
-250.54M▼ 19.7%
-246.17M▲ 1.7%
-78.82M▲ 68.0%
-51.02M▲ 35.3%
-59.2M▲ 0%
Equity Growth %-16.96%18.46%-8.82%5.3%-16.03%-19.67%1.74%67.98%35.26%188.68%
Book Value per Share-2.06-1.21-0.97-0.81-0.84-0.97-0.92-0.28-0.16-0.19
Total Shareholders' Equity-214.73M-175.08M-190.53M-180.42M-209.35M-250.54M-246.17M-78.82M-51.02M-59.2M
Common Stock1.19M1.87M2.12M2.42M2.52M2.64M2.7M3.03M3.08M3.09M
Retained Earnings-2.85B-2.94B-2.99B-3.05B-3.13B-3.22B-3.23B-3.2B-3.2B-3.21B
Treasury Stock0000000000
Accumulated OCI-18K-19K-19K00001.11M115K-4K
Minority Interest0000000000

MNKD Cash Flow Statement

MannKind Corporation (MNKD) cash flow — operating, investing & free cash flow history

Line itemDec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25TTM
Cash from Operations-64.78M-37.73M-88.48M-28.13M-61.71M-80.7M34.09M42.51M18.25M18.25M
Operating CF Margin %-551.54%-135.44%-140.36%-43.18%-81.8%-80.88%17.14%14.89%5.23%-
Operating CF Growth %17.05%41.75%-134.51%68.21%-119.39%-30.77%142.25%24.69%-57.06%165.92%
Net Income-117.33M-86.97M-51.9M-57.24M-80.93M-87.4M-11.94M27.59M5.86M-23.91M
Depreciation & Amortization3.53M1.7M2.15M3.33M5.47M6.29M5.8M9.04M12.28M15.97M
Stock-Based Compensation4.85M6.86M6.2M6.51M12.2M017.65M21.36M24.2M20.95M
Deferred Taxes12.94M0-4.57M10.65M12.64M000-4.97M-4.97M
Other Non-Cash Items3.67M5.71M-28M18.4M6.63M24.47M7.96M21M67.23M95.53M
Working Capital Changes27.57M36.68M-12.36M-9.78M-17.73M-24.05M14.63M-36.47M-86.35M-84.45M
Change in Receivables-2.49M-1.34M504K-705K-776K-11.81M2.35M2.65M-4.76M22.62M
Change in Inventory-3.3M-3.15M-558K-1.31M-4.08M-5.67M4.57M-3.2M10.4M-15.47M
Change in Payables3.8M-1.6M-593K793K1.37M4.1M-1.47M-2.79M-16.71M-7.85M
Cash from Investing16.68M-234K-22.84M15.22M-151.54M4.87M-1.99M-96.65M-304.8M-292.04M
Capital Expenditures0-354K-2.56M-4.78M-11.47M-7.59M-42.44M-9.69M-4.57M-6.12M
CapEx % of Revenue-1.27%4.07%7.34%15.2%7.61%21.33%3.4%1.31%-
Acquisitions24K120K0-3.98M-56.06M-15.34M00-347.74M-347.74M
Investments----------
Other Investing16.68M120K-300K20M56.06M32.8M382K128.71M-16.41M-10M
Cash from Financing73.56M61.29M69.86M49.85M270.27M21.41M136.61M-137.27M315.1M278.46M
Debt Issued (Net)15.43M-5M63.7M14.87M281.08M-1.09M-6.86M-133.17M074.19M
Equity Issued (Net)58.25M70.52M3.2M23.66M1.89M22.56M6.89M-6.09M-3.26M7.3M
Dividends Paid0000000000
Share Repurchases0000000000
Other Financing-120K-4.22M2.97M11.31M-12.7M-62K136.58M1.99M318.36M196.97M
Net Change in Cash
25.46M▲ 0%
23.33M▼ 8.4%
-41.46M▼ 277.7%
36.94M▲ 189.1%
57.02M▲ 54.4%
-54.42M▼ 195.4%
168.71M▲ 410.0%
-191.4M▼ 213.4%
28.55M▲ 114.9%
5.53M▲ 0%
Free Cash Flow
-64.78M▲ 0%
-38.09M▲ 41.2%
-91.05M▼ 139.1%
-32.91M▲ 63.9%
-73.17M▼ 122.3%
-88.29M▼ 20.7%
-8.35M▲ 90.5%
32.82M▲ 493.2%
13.69M▼ 58.3%
13M▲ 0%
FCF Margin %-551.54%-136.71%-144.43%-50.52%-97%-88.49%-4.2%11.49%3.92%3.6%
FCF Growth %18.24%41.21%-139.07%63.85%-122.34%-20.65%90.55%493.17%-58.29%-40.42%
FCF per Share-0.62-0.26-0.47-0.15-0.29-0.34-0.030.120.040.04
FCF Conversion (FCF/Net Income)0.55x0.43x1.70x0.49x0.76x0.92x-2.86x1.54x3.11x-0.54x
Interest Paid7.73M3.76M00000002.56M
Taxes Paid51K240K0000000869K

MNKD Key Ratios

MannKind Corporation (MNKD) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric201720182019202020212022202320242025TTM
Return on Equity (ROE)---------45.59%
Return on Invested Capital (ROIC)--------21.55%21.55%
Gross Margin-46.68%26.49%55.62%62.17%48.49%42.37%68.45%73.17%82.47%79.25%
Net Margin-999%-312.2%-82.34%-87.87%-107.27%-87.6%-6%9.66%1.68%-6.63%
Debt / Equity----------0.17x
Interest Coverage-7.83x-8.19x-3.76x-5.07x-3.88x-2.53x0.42x1.80x1.10x0.75x
FCF Conversion0.55x0.43x1.70x0.49x0.76x0.92x-2.86x1.54x3.11x-0.54x
Revenue Growth-93.28%137.2%126.28%3.34%15.81%32.25%99.42%43.5%22.23%21.23%

MNKD SEC Filings & Documents

MannKind Corporation (MNKD) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

May 6, 2026·SEC

Material company update

Feb 26, 2026·SEC

Material company update

Nov 10, 2025·SEC

10-K Annual Reports

3
FY 2026

Feb 26, 2026·SEC

FY 2025

Feb 26, 2025·SEC

FY 2024

Feb 27, 2024·SEC

10-Q Quarterly Reports

6
FY 2026

May 6, 2026·SEC

FY 2025

Nov 5, 2025·SEC

FY 2025

Aug 6, 2025·SEC

MNKD Frequently Asked Questions

MannKind Corporation (MNKD) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

MannKind Corporation (MNKD) reported $360.8M in revenue for fiscal year 2025.

MannKind Corporation (MNKD) grew revenue by 22.2% over the past year. This is strong growth.

MannKind Corporation (MNKD) reported a net loss of $23.9M for fiscal year 2025.

Dividend & Returns

MannKind Corporation (MNKD) generated $13.0M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

Explore More MNKD

MannKind Corporation (MNKD) financial analysis — history, returns, DCA and operating performance tools

Total Return Calculator

Historical returns with dividends reinvested

→

DCA Calculator

Dollar cost averaging vs lump sum

→

Dividend History

Yield, growth, payout safety & DRIP

→

Earnings History

EPS trends, net income & profitability

→

Price History

Long-term charts & historical price data

→

Revenue History

Sales growth patterns & revenue breakdown

→

Financial Ratios

30 years of market, efficiency and balance-sheet ratios

→

Valuation

DCF intrinsic value, peer multiples & estimates

→
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screener
  • Themes
  • Market Valuation
  • Valuation
  • Compare
  • Total Return
  • DCA Calculator
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Follow @VCPScanner on X

Get weekly stock ideas — free

© 2026 VCP Scanner. All rights reserved.
About·Privacy Policy·Terms of Service
Not financial advice. Do your own research.